Elvan Onur KIRIMLAR, Hakan KUMBASAR, Berker DUMAN, Meltem Bingöl KOLOĞLU, Oğuzhan HERDİ, Burçin ÇOLAK, Mehmet Kaan KARAYALÇIN, Deniz BALCI

The association between tacrolimus blood levels and possible neurotoxicity following liver transplantation

Aim: Tacrolimus is an immunosuppressive agent used for prophylaxis of organ rejection after solid organ transplantations.Neuropsychiatric adverse effects that occur in the first 4 weeks following initiation of tacrolimus defined as early tacrolimus-inducedneurotoxicity (TIN). In our study, we aimed to determine the incidence of possible TIN and to examine its association with tacrolimusblood levels and establish other medical and clinical factors to predict in patients with liver transplantation.Material and Methods: This retrospective, single-center study was conducted at a transplantation unit of tertiary level universityhospital. All the patients were enrolled, who undergone liver transplantation between January 2013 and December 2018. Tacrolimusblood levels were obtained the day after the initiation of tacrolimus and for consecutive 10 days. All the patients z-scores calculatedfor tacrolimus mean blood levels until index day. Index day is defined as ‘the day of diagnosis of possible TIN’. Age, gender, previousencephalopathy, cadaveric/live donor transplantation, pre-transplantation MELD score, CRP levels and tacrolimus blood levels wereinvestigated as predictors of possible neuropsychiatric events following liver transplantation in two weeks.Results: Tacrolimus z-scores were detected to be significantly different between groups; found to be lower in the possible tacrolimusinduced neurotoxicity group compared to the control group (t=2.607, p=0.01). Pre-transplantation model significantly predictsneuropsychiatric adverse events(χ²(7)=16.049, p=0.035).Conclusion: To our knowledge, this is the first study that shows an inverse association with tacrolimus blood levels and possibleTIN; which requires consideration. It is obvious that further well designed, prospective studies are needed to clearly establish riskfactors for TIN.

PDF

___

1. Emiroglu R, Ayvaz I, Moray G, et al. Tacrolimusrelated neurologic and renal complications in liver transplantation: A single-center experience. Transplant Proc 2006;38:619-21.
2. Balderramo D, Prieto J, Cárdenas A, et al. Hepatic encephalopathy and post-transplant hyponatremia predict early calcineurin inhibitor-induced neurotoxicity after liver transplantation. Transpl Int 2011;24:812-9.
3. Aminzadeh A, Sharifi AM. Tacrolimus toxicity in organ transplantation: an overview. Arch Med Sci 2017;3:31- 6.
4. Zhang W, Egashira N, Masuda S. Recent Topics on The Mechanisms of Immunosuppressive Therapy-Related Neurotoxicities. Int J Mol Sci 2019;20:3210.
5. Heits N, Keserovic D, Mund N, et al. Cognitive Evaluation in Liver Transplant Patients Under Calcineurin Inhibitor Maintenance Therapy. Transplant Direct 2017;3:146.
6. Anghel D, Tanasescu R, Campeanu A, et al. Neurotoxicity of immunosuppressive therapies in organ transplantation. Maedica 2013;8:170-5.
7. Sakomoto Y, Kakuuchı M, Harıhara Y, et al. Correlation between Neurotoxic Events and Intracerebral Concentration of Tacrolimus in Rats. Bio Pharm Bull 2000;23:1008-10.
8. Böttiger Y, Brattström C, Tydén G, et al. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999;48:445-8.
9. Bechstein WO. Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transpl Int 2000;13:313-26.
10. DiMartini A, Fontes P, Dew MA, et al. Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicity. Liver Transpl 2008;14:815-22.
11. Kim KM, Kim GS, Ko JS, et al. Factors associated with consciousness recovery time after liver transplantation in recipients with hepatic encephalopathy. Transplant Proc 2014;46:712-5.
12. Wijdicks E. Neurotoxicity of immunosuppressive drugs. Liver Transpl 2001;7:937-42.
13. Zivković SA. Neurologic complications after liver transplantation. World J Hepatol 2013;5:409-16.
14. Lué A, Martinez E, Navarro M, et al. Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation.Transplantation 2019;103:211-5.
15. Wu SY, Chen TW, Feng AC, et al. Comprehensive risk assessment for early neurologic complications after liver transplantation. World J Gastroenterol 2016;22:5548-57.
16. An HJ, Jang JW, Bae SH, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2012;18:1406-14.
17. Kim YK, Kim SH, Lee SD, et al. Pretransplant serum levels of C-reactive protein predict prognoses in patients undergoing liver transplantation for hepatocellular carcinoma. Transplant Proc 2015;47:686-93.